Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
603-03-007 / 271-01-014 ISMRM Abstract

Context is everything: Reducing false positives in longitudinal health assessment using deep learning with prior information

Primary: Analysis Methods - Classification and Prediction
Secondary: Body - Prostate
603-03-007 · AI for Diagnostic and Prognostic Applications · Thursday, 14 May, 4:00 PM–5:50 PM · Auditorium 1
271-01-014 · ISMRM AMPC Selected Posters · Sunday, 10 May, 7:00 AM–2:00 PM · Traditional Posters
Keywords: Diagnosis/Prediction Machine Learning/Artificial Intelligence Prostate cancer Longitudinal Studies Risk Stratification
Accepted
Lavanya Umapathy1,2, Patricia M Johnson1,2, Tarun Dutt2, Angela Tong1, Madhur Nayan3,4, Hersh Chandarana1,2, Daniel K Sodickson 1,2
1Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York University Grossman School of Medicine, New York, New York, United States of America
2Center for Advanced Imaging Innovation and Research (CAI²R), New York University Grossman School of Medicine, New York, United States of America
3Department of Urology, New York University Grossman School of Medicine, New York, United States of America
4Department of Population Health, New York University Grossman School of Medicine, New York, United States of America
Presenting Author: Daniel K Sodickson

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Al Awamlh BA, Barocas DA, Zhu AL, et al. Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018. Jama Intern Med 2023;183(6):608-11 doi: 10.1001/jamainternmed.2022.7100. [doi]
2. Schmitz RSJM, Engelhardt EG, Gerritsma MA, et al. Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial. Eur J Cancer 2023;192 doi: ARTN 113276 10.1016/j.ejca.2023.113276. [doi]
3. Pickhardt PJ, Summers RM, Garrett JW, et al. Opportunistic Screening: Scientific Expert Panel. Radiology 2023;307(5) doi: ARTN e222044 10.1148/radiol.222044. [doi]
4. Knudsen AB, Trentham-Dietz A, Kim JJ. Estimated US Cancer Deaths Prevented With Increased Use of Lung, Colorectal, Breast, and Cervical Cancer Screening (vol 6, e2344698, 2023). Jama Netw Open 2023;6(12) doi: ARTN e2351369 10.1001/jamanetworkopen.2023.51369. [doi]
5. Esserman LJ, Thompson IM, Reid B. Overdiagnosis and Overtreatment in Cancer An Opportunity for Improvement. Jama-J Am Med Assoc 2013;310(8):797-98 doi: 10.1001/jama.2013.108415. [doi]
6. Kilpeläinen TP, Tammela TLJ, Roobol M, et al. False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer 2011;47(18):2698-705 doi: 10.1016/j.ejca.2011.06.055. [doi]
7. Miglioretti DL, Abraham L, Sprague BL, et al. Association Between False-Positive Results and Return to Screening Mammography in the Breast Cancer Surveillance Consortium Cohort. Ann Intern Med 2024;177(10):1297-307 doi: 10.7326/M24-0123. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/603-03-007